254. ポルフィリン症 Porphyria Clinical trials / Disease details
臨床試験数 : 70 / 薬物数 : 54 - (DrugBank : 19) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02979249 (ClinicalTrials.gov) | December 2016 | 29/11/2016 | Oral Iron for Erythropoietic Protoporphyrias | Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias | Erythropoietic Protoporphyria;EPP;X-linked Protoporphyria;XLP | Drug: Oral Iron | Icahn School of Medicine at Mount Sinai | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 18 Years | N/A | All | 16 | N/A | United States |
2 | NCT01284946 (ClinicalTrials.gov) | January 2011 | 26/1/2011 | Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda | A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload | Porphyria Cutanea Tarda | Drug: Exjade | Assistance Publique - Hôpitaux de Paris | Association pour l'Etude des Fonctions Digestives (AEFD) | Recruiting | 18 Years | N/A | Both | 45 | Phase 2 | France |